Interventional Therapy Sequential With the Fourth-generation CAR-T Targeting Nectin4/FAP for Malignant Solid Tumors
Keywords
Abstract
Description
Currently, malignant tumors are the leading cause of death. Surgery, chemotherapy, radiation therapy, and targeted therapy have become the four foundations of cancer treatment for many years. With the development of science and technology, immunotherapy has become the "fifth pillar" of cancer treatment. The most hot topic in immunotherapy is CAR-T therapy. The basic principle of CAR-T therapy (chimeric antigen receptor-T cells) is mainly to use the patient's own immune cells to clear cancer cells. CAR is a core component of CAR-T, conferring T cell a HLA-independent way to recognize tumor antigens, allowing CAR-modified T cells to recognize a broader target than the natural T cell surface receptor TCR. The basic design of CAR includes a tumor associated antigen (TAA) binding region, an extracellular hinge region, a transmembrane region and an intracellular signaling region. The selection of target antigens is a key determinant of the specificity and effectiveness of CAR and the safety of genetically modified T cells themselves.
Nectin-4 is a type I transmembrane protein whose extracellular domain is composed of three Ig-like domains (V-C-C type), which together with cadherin participate in the formation and maintenance of adhesion junctions. Nectin-4 is ubiquitously expressed in human embryonic cells but is hardly expressed in normal adult tissues. Nectin-4 is highly expressed on the surface of breast cancer, bladder cancer, non-small cell lung cancer, and pancreatic cancer cells, and plays a key role in the occurrence, invasion and metastasis of these epithelial malignancies. In conclusion, Nectin-4 is one of the important targets for the diagnosis and treatment of many solid tumors. The antibody-conjugated drug Enfortumab Vedotin targeting Nectin-4 was highly effective in Phase I clinical trials in 81 advanced bladder cancers, and was awarded FDA breakthrough therapy in March 2018. Fibroblast activation protein (FAP) belongs to the serine protease family and is highly expressed on the surface of cancer-associat
Dates
| Last Verified: | 03/31/2019 |
| First Submitted: | 04/26/2019 |
| Estimated Enrollment Submitted: | 04/26/2019 |
| First Posted: | 04/29/2019 |
| Last Update Submitted: | 04/26/2019 |
| Last Update Posted: | 04/29/2019 |
| Actual Study Start Date: | 02/12/2019 |
| Estimated Primary Completion Date: | 06/29/2021 |
| Estimated Study Completion Date: | 12/30/2021 |
Condition or disease
Intervention/treatment
Biological: The fourth-generation CAR-T therapy
Phase
Arm Groups
| Arm | Intervention/treatment |
|---|---|
| Experimental: The fourth-generation CAR-T therapy Clinical trial study of Interventional therapy sequential with the fourth-generation CAR-T cells (IL7 and CCL19 or / and IL12) targeting Nectin4/FAP in the treatment of advanced malignant solid tumors with Nectin4-positive . | Biological: The fourth-generation CAR-T therapy The Intravenous minimally invasive surgery combined with intratumoral injection of Nectin4/FAP-targeted the fourth-generation CAR-T cells (expressing IL7 and CCL19, or IL12) are used to treat Nectin4-positive advanced malignant solid tumors, maximally eliminating residual cancer cells and preventing recurrence. |
Eligibility Criteria
| Ages Eligible for Study | 18 Years To 18 Years |
| Sexes Eligible for Study | All |
| Accepts Healthy Volunteers | Yes |
| Criteria | Inclusion Criteria: 1. Patients who meet the requirements voluntarily participate in the study and sign the Informed Consent Form. 2. Age is 18 to 75 years old, gender is not limited; the Eastern Cancer Cooperative Group (ECOG) scores 0 to 3 3. Pathological diagnosis of malignant solid tumors. 4. Advanced malignant solid tumors meet the CSCO malignant tumor diagnosis and treatment guidelines (2018 version). (Flow or pathology shows that tumor cells express Nectin4 antigen and tumor-associated fibroblasts express FAP antigen) 5. Head magnetic resonance or CT examination showed no central invasion of malignant tumors. 6. Collection of peripheral blood mononuclear cells must be more than 2 weeks from radiotherapy and chemotherapy. 7. Peripheral blood neutrophils number ≥ 1000 / μl, platelets ≥ 50,000 / μl. 8. Heart, liver and kidney function: creatinine <2.5mg/dl; ALT (alanine aminotransferase) / AST (aspartate aminotransferase) <3 times lower than the upper limit of normal; total bilirubin <2.0mg/dl. 9. Cardiac ejection fraction (EF) ≥ 50%, echocardiography without pericardial effusion. 10. Have fertility must be willing to use contraceptive methods. 11. The expected survival period is more than 12 weeks. 12. No other malignant tumors, severe autoimmune diseases or congenital immunodeficiency, serious progressive infection, cranial nerve disorder or mental illness. Exclusion Criteria: 1. Pregnant or lactating women. 2. Patients with uncontrollable active infections. 3. Patients with systemic steroids; recent or current use of inhaled steroids is not excluded. 4. Previously involved CAR-T cell therapies produced any uncontrolled disease. |
Outcome
Primary Outcome Measures
1. Adverse events that are related to treatment [2 years]
Secondary Outcome Measures
1. 2 year overall survival(OS) [2 years]
2. 3 year progression free survival (PFS) [3 years]
